

REFERENCES

1. Beaglehole R et al. *Preventing chronic diseases: a vital investment*. Geneva, WorldHealth Organization, 2005.
2. Strong K et al. Preventing chronic diseases: how many lives can we save? *The Lancet*, 2005, 366:1578–1582.
3. Lee J. Global health improvement and WHO: shaping the future. *The Lancet*, 2003, 366:1821–1824.
4. Srinath RK. Responding to the threat of chronic diseases in India. *The Lancet*, 2005, 366:1744–1749.
5. Wang L. Preventing chronic diseases in China. *The Lancet*, 2005, 366:1821–1824.
6. Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. *Bulletin of the World Health Organization*, 1994, 72:429–445.
7. *The World Health Report 2002: reducing risks, promoting healthy life*. Geneva, World Health Organization, 2002.
8. Lyttkens CH. Time to disable DALYs? On the use of disability-adjusted life years in health policy. *European Journal of Health Economics*, 2003, 4:195–202.
9. Beaglehole R, Yach D. Globalization and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. *The Lancet*, 2003, 362:903–908.
10. Prescott E et al. Social position and mortality from respiratory diseases in males and females. *European Respiratory Journal*, 2003, 21:821–826.
11. Epping-Jordan J et al. Preventing chronic diseases: taking stepwise action. *The Lancet*, 2005, 366:1667–1671.
12. Su T, Kouyaté B, Flessa S. Catastrophic household expenditure for health care in a low-income society: a study from Nouna District, Burkina Faso. *Bulletin of the World Health Organization*, 2006, 84:21–27.
13. Bousquet J et al. Management of chronic respiratory and allergic diseases in developing countries. Focus on sub-Saharan Africa. *Allergy*, 2003, 58:265–283.
14. Enarson DA, Ait-Khaled N. Cultural barriers to asthma management. *Pediatric Pulmonology*, 1999, 28:297–300.
15. Masoli M et al. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. *Allergy*, 2004, 59:469–478.
16. Ford ES. The epidemiology of obesity and asthma. *Journal of Allergy and Clinical Immunology*, 2005, 115:897–909.
17. Ait-Khaled N et al. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. *The International Journal of Tuberculosis and Lung Disease*, 2000, 4:268–271.

18. Quick JD. Medicines supply in Africa. *British Medical Journal*, 2005, 331:709–710.
19. The Bamako initiative. *The Lancet*, 1988, 2:1177–1178.
20. Kale R. Traditional healers in South Africa: a parallel health care system. *British Medical Journal*, 1995, 310:1182–1185.
21. Siddiqi K, Newell J. Putting evidence into practice in low-resource settings. *Bulletin of the World Health Organization*, 2005, 83:882–883.
22. Fairall LR et al. Effect of educational outreach to nurses on tuberculosis case detection and primary care of respiratory illness: pragmatic cluster randomized controlled trial. *British Medical Journal*, 2005, 331:750–754.
23. Ait-Khaled N, Enarson DA. *Management of asthma. A guide to the essential good of good clinical practice*. 2nd edition. Paris, International Union Against Tuberculosis and Lung Disease, 2005.
24. *WHO strategy for prevention and control of chronic respiratory diseases*. Geneva, World Health Organization, 2002 (http://whqlibdoc.who.int/hq/2002/WHO_MNC_CRA_02.1.pdf, accessed 8 February 2007).
25. *Implementation of the WHO strategy for prevention and control of chronic respiratory diseases: Meeting report 11–12 February 2002, Montpellier*. Geneva, World Health Organization, 2002 (http://whqlibdoc.who.int/HQ/2002/WHO_MNC_CRA_02.2.pdf, accessed 8 February 2007).
26. *Prevention and control of chronic respiratory diseases in low- and middle-income African countries: a preliminary report*. Geneva, World Health Organization, 2003 (http://whqlibdoc.who.int/hq/2003/WHO_NMH_CRA_04.1.pdf, accessed 8 February 2007).
27. *Prevention and control of chronic respiratory diseases at country level: towards a Global Alliance against Chronic Respiratory Diseases*. Geneva, World Health Organization, 2005 (http://whqlibdoc.who.int/hq/2005/WHO_NMH_CHP_CPM_CRA_05.1.pdf, accessed 8 February 2007).
28. Khaltav N. WHO strategy for prevention and control of chronic obstructive pulmonary disease. *Experimental Lung Research*, 2005, 31:55–56.
29. *International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2006*. Geneva, World Health Organization, 2006.
30. *World Population Prospects. The 2006 Revision. Highlights*. New York, United Nations, 2007.
31. Ahmad, et al. Age Standardization of Rates: a new WHO standard. *GPE Discussion Paper Series: No.31*. Geneva, World Health Organization, 2007.
32. Halbert R, et al. Global burden of COPD: systematic review and meta-analysis. *European Respiratory Journal*, 2006, 523–532.
33. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *The Lancet*, 1998, 351:1225–1232.
34. Janson C et al. The European Community Respiratory Health Survey: what are the main results so far? *European Respiratory Journal*, 2001, 18:598–611.
35. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. *Allergy*, 2005, 60:350–353.
36. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *European Respiratory Journal*, 2004, 24:758–764.
37. Pearce N, Douwes J, Beasley R. Is allergen exposure the major primary cause of asthma? *Thorax*, 2000, 55:424–431.
38. Ross MH, Murray J. Occupational respiratory disease in mining. *Occupational Medicine*, 2004, 54:304–310.

39. Wang XR, Christiani DC. Occupational lung disease in China. *International Journal of Occupational and Environmental Health*, 2003, 9:320–325.
40. Barbosa MM et al. Pulmonary hypertension in schistosomiasis mansoni. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 1996, 90:663–665.
41. Powars DR et al. Outcome of sickle cell anemia: a 4–decade observational study of 1056 patients. *Medicine*, 2005, 84:363–376.
42. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. *British Journal of Haematology*, 2005, 129:449–464.
43. Aldashev AA et al. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. *American Journal of Respiratory and Critical Care Medicine*, 2002, 166:1396–1402.
44. Ge RL, Helun G. Current concept of chronic mountain sickness: pulmonary hypertension-related high-altitude heart disease. *Wilderness and Environmental Medicine Journal*, 2001, 12:190–194.
45. Gislason T et al. Prevalence of sleep apnea syndrome among Swedish men—an epidemiological study. *Journal of Clinical Epidemiology*, 1988, 41:571–576.
46. Enright PL et al. Prevalence and correlates of snoring and observed apneas in 5,201 older adults. *Sleep*, 1996, 19:531–538.
47. Ohayon MM et al. Snoring and breathing pauses during sleep: telephone interview survey of a United Kingdom population sample. *British Medical Journal*, 1997, 314:860–863.
48. Larsson LG et al. Gender differences in symptoms related to sleep apnea in a general population and in relation to referral to sleep clinic. *Chest*, 2003, 124:204–211.
49. Ottmani S, et al. *Respiratory care in primary care services. A survey in 9 countries*. Geneva, World Health Organization, 2004.
50. *GINA Report, Global strategy for asthma management and prevention (revised 2006)*. Global Initiative for Asthma, 2007.
51. Bousquet J, Khaltaev N, van Cauwenbergue P. Allergic rhinitis and its impact on asthma. *Journal of Allergy and Clinical Immunology*, 2001, 108 (5 Suppl):S147–334.
52. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). *European Respiratory Journal*, 1996, 9:687–695.
53. Law M et al. Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. *British Medical Journal*, 2005, 330:1187–1188.
54. Rosado-Pinto J, Morais-Almeida M. Asthma in the developing world. *Pediatric Pulmonology*, 2004, 26 (suppl.):66–68.
55. von Hertzen L, Morais-Almeida M. Signs of reversing trends in prevalence of asthma. *Allergy*, 2005, 60:283–292.
56. Linneberg A. Changes in atopy over 25 years: allergy epidemic has spread to old age. *British Medical Journal*, 2005, 331:352.
57. Jarvis D et al. Change in prevalence of IgE sensitization and mean total IgE with age and cohort. *Journal of Allergy and Clinical Immunology*, 2005, 116:675–682.
58. Hahtela T et al. Asthma programme in Finland: a community problem needs community solutions. *Thorax*, 2001, 56:806–814.
59. Ait-Khaled N et al. The Asthma Workshop. Report of a workshop organised by the International Union Against Tuberculosis and Lung Disease, Paris, 15–16 December 2000. *The International Journal of Tuberculosis and Lung Disease*, 2001, 5:973–977.

60. Fischer GB, Camargos PA, Mocelin HT. The burden of asthma in children: a Latin American perspective. *Paediatric Respiratory Reviews*, 2005, 6:8–13.
61. Warman KL, Silver EJ, Stein RE. Asthma symptoms, morbidity, and anti-inflammatory use in inner-city children. *Pediatrics*, 2001, 108:277–282.
62. Bousquet J et al. Quality of life in asthma. Internal consistency and validity of the SF-36 questionnaire. *American Journal of Respiratory and Critical Care Medicine*, 1994, 149:371–375.
63. Leynaert B et al. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. *American Journal of Respiratory and Critical Care Medicine*, 2000, 162:1391–1396.
64. Fighting for breath. A European patient perspective on severe asthma. Brussels, EFA, 2005. (http://www.efanet.org/activities/documents/Fighting_For_Breath1.pdf, accessed 8 February 2007).
65. Tartasky D. Asthma in the inner city: a growing public health problem. *Holistic Nursing Practice*, 1999, 14:37–46.
66. Bonilla S et al. School absenteeism in children with asthma in a Los Angeles inner city school. *Journal of Pediatrics*, 2005, 147:802–806.
67. Guevara JP et al. Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis. *British Medical Journal*, 2003, 326:1308–1309.
68. *The world health report 2004: changing history*. Geneva, World Health Organization, 2004.
69. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. *Journal of Allergy and Clinical Immunology*, 2001, 107:3–8.
70. Sculpher MJ, Price M. Measuring costs and consequences in economic evaluation in asthma. *Respiratory Medicine*, 2003, 97:508–520.
71. Godard P et al. Costs of asthma are correlated with severity: a 1-yr prospective study. *European Respiratory Journal*, 2002, 19:61–67.
72. Yeatts K et al. Health consequences for children with undiagnosed asthma-like symptoms. *Archives of Pediatrics & Adolescent Medicine*, 2003, 157:540–544.
73. Amre DK et al. Socioeconomic status and utilization of health care services among asthmatic children. *Journal of Asthma*, 2002, 39:625–631.
74. Lodha R et al. Social and economic impact of childhood asthma. *Indian Journal of Pediatrics*, 2003, 40:874–879.
75. Evans R et al. A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study. *Journal of Pediatrics*, 1999, 135:332–338.
76. Cloutier MM et al. Use of asthma guidelines by primary care providers to reduce hospitalizations and emergency department visits in poor, minority, urban children. *Journal of Pediatrics*, 2005, 146:591–597.
77. Leynaert B et al. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. *Journal of Allergy and Clinical Immunology*, 1999, 104:301–304.
78. Leynaert B et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. *Journal of Allergy and Clinical Immunology*, 2004, 113:86–93.
79. Bugiani M et al. Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. *Allergy*, 2005, 60:165–170.
80. Bousquet et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS

- study group. *Clinical and Experimental Allergy*, 2005, 35:728–732.
81. Strachan D et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). *Pediatric Allergy and Immunology*, 1997, 8:161–176.
 82. Esamai F, Ayaya S, Nyandiko W. Prevalence of asthma, allergic rhinitis and dermatitis in primary school children in Uasin Gishu district, Kenya. *East African Medical Journal*, 2002, 79:514–518.
 83. Falade AG et al. Prevalence and severity of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema in 6- to 7-year-old Nigerian primary school children: the international study of asthma and allergies in childhood. *Medical Principles and Practice*, 2004, 13:20–25.
 84. Hailu S, Tessema T, Silverman M. Prevalence of symptoms of asthma and allergies in schoolchildren in Gondar town and its vicinity, northwest Ethiopia. *Pediatric Pulmonology*, 2003, 35:427–432.
 85. Lee SL, Wong W, Lau YL. Increasing prevalence of allergic rhinitis but not asthma among children in Hong Kong from 1995 to 2001 (Phase 3 International Study of Asthma and Allergies in Childhood). *Pediatric Allergy and Immunology*, 2004, 15:72–78.
 86. Teeratakulpisarn J, Pairojkul S, Heng S. Survey of the prevalence of asthma, allergic rhinitis and eczema in schoolchildren from Khon Kaen, Northeast Thailand. an ISAAC study. International Study of Asthma and Allergies in Childhood. *Asian Pacific Journal of Allergy and Immunology*, 2000, 18:187–194.
 87. Asher MI et al. The burden of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema in children and adolescents in six New Zealand centres: ISAAC Phase One. *The New Zealand Medical Journal*, 2001, 114:114–120.
 88. Akcakaya N et al. Prevalence of bronchial asthma and allergic rhinitis in Istanbul school children. *European Journal of Epidemiology*, 2000, 16:693–699.
 89. Vanna AT et al. International Study of Asthma and Allergies in Childhood: validation of the rhinitis symptom questionnaire and prevalence of rhinitis in schoolchildren in Sao Paulo, Brazil. *Pediatric Allergy and Immunology*, 2001, 12:95–101.
 90. Shamssain MH, Shamsian N. Prevalence and severity of asthma, rhinitis, and atopic eczema in 13- to 14-year-old schoolchildren from the northeast of England. *Annals of Allergy, Asthma and Immunology*, 2001, 86:428–432.
 91. Burney P et al. The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. *Journal of Allergy and Clinical Immunology*, 1997, 99:314–322.
 92. Sunyer J et al. Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study. *Journal of Allergy and Clinical Immunology*, 2004, 114:1033–1039.
 93. Sears MR et al. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. *Clinical and Experimental Allergy*, 1989, 19:419–424.
 94. Wahn U, Von Mutius E. Childhood risk factors for atopy and the importance of early intervention. *Journal of Allergy and Clinical Immunology*, 2001, 107:567–574.
 95. Keil T et al. European birth cohort studies on asthma and atopic diseases: I. Comparison study of designs – a GA²LEN initiative. *Allergy*, 2006, 61:221–228.
 96. Keil T. European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures – a GA²LEN initiative. *Allergy*, 2006, 61:1104–1111.
 97. Guerra S et al. Rhinitis as an independent risk factor for adult-onset asthma. *Journal of Allergy and Clinical Immunology*, 2002, 109:419–425.
 98. Illi S et al. The natural course of atopic dermatitis from birth to age 7 years and the

- association with asthma. *Journal of Allergy and Clinical Immunology*, 2004, 113:925–931.
99. Spergel JM. Atopic march: link to upper airways. *Current Opinion in Allergy and Clinical Immunology*, 2005, 5:17–21.
 100. Beeh KM et al. Cigarette smoking, but not sensitization to *Alternaria*, is associated with severe asthma in urban patients. *Journal of Asthma*, 2001, 38:41–49.
 101. Lange P et al. A 15-year follow-up study of ventilatory function in adults with asthma. *New England Journal of Medicine*, 1998, 339:1194–1200.
 102. Tomlinson JE et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. *Thorax*, 2005, 60:282–287.
 103. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. *European Respiratory Journal*, 2004, 24:822–833.
 104. Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Medicine*, 2006, e442.
 105. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report*. National Institutes of Health, National Heart, Lung and Blood Institute, 2001.
 106. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *European Respiratory Journal*, 2004, 23:932–946.
 107. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Update 2005*. National Institutes of Health, National Heart, Lung and Blood Institute, 2005.
 108. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, 1995, 152(5 Pt 2): S77–S121.
 109. Pauwels R et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *American Journal of Respiratory and Critical Care Medicine*, 2001, 163:1256–1276.
 110. Guerra S. Overlap of asthma and chronic obstructive pulmonary disease. *Current Opinion in Allergy and Clinical Immunology*, 2005, 11:7–13.
 111. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Update 2003*. National Institutes of Health, National Heart, Lung and Blood Institute, 2003.
 112. Hogg JC et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *New England Journal of Medicine*, 2004, 350:2645–2653.
 113. Mannino DM, Doherty DE, Buist SA. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. *Respiratory Medicine*, 2006, 100:115–122.
 114. Chapman K et al. Epidemiology and costs of chronic obstructive pulmonary disease. *European Respiratory Journal*, 2006, 27:188–207.
 115. Chan-Yeung M et al. The burden and impact of COPD in Asia and Africa. *The International Journal of Tuberculosis and Lung Disease*, 2004, 8:2–14.
 116. Lopez AD, et al. Chronic obstructive pulmonary disease: current burden and future projections. *European Respiratory Journal*, 2006, 27:397–412.
 117. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). *The Lancet*, 2004, 364:613–620.
 118. Lindberg A et al. Prevalence of chronic obstructive pulmonary disease according to

- BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. *Respiration*, 2005, 72:471–479.
119. Lacasse Y et al. The validity of diagnosing chronic obstructive pulmonary disease from a large administrative database. *Canadian Respiratory Journal*, 2005, 12:251–256.
 120. Viegi G et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. *Chest*, 2000, 117(5 Supplement 2):339S–345S.
 121. Halbert RJ et al. Interpreting COPD prevalence estimates: what is the true burden of disease? *Chest*, 2003, 123:1684–1692.
 122. Celli BR et al. Population impact of different definitions of airway obstruction. *European Respiratory Journal*, 2003, 22:268–273.
 123. Viegi G et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. *Chest*, 2004, 126:1093–1101.
 124. Fukuchi Y et al. COPD in Japan: the Nippon COPD Epidemiology study. *Respirology*, 2004, 9:458–465.
 125. Loddenkemper R, Gibson G, Sibille Y. *European lung white book - the first comprehensive survey on respiratory health in Europe*. Huddersfield, European Respiratory Society, 2003.
 126. de Marco R et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. *Thorax*, 2004, 59:120–125.
 127. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination. *Journal of Internal Medicine*, 2003, 254:540–547.
 128. Lange P et al. Chronic obstructive lung disease in Copenhagen: cross-sectional epidemiological aspects. *Journal of Internal Medicine*, 1989, 226:25–32.
 129. Dickinson JA et al. Screening older patients for obstructive airways disease in a semi-rural practice. *Thorax*, 1999, 54:501–505.
 130. Isoaho R et al. Prevalence of chronic obstructive pulmonary disease in elderly Finns. *Respiratory Medicine*, 1994, 88:571–580.
 131. von Hertzen L et al. Airway obstruction in relation to symptoms in chronic respiratory disease – a nationally representative population study. *Respiratory Medicine*, 2000, 94:356–363.
 132. Gulsvik A. Prevalence and manifestations of obstructive lung disease in the city of Oslo. *Scandinavian Journal of Respiratory Diseases*, 1979, 60:286–296.
 133. Bakke S et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. *Thorax*, 1991, 46:863–870.
 134. Marco-Jordan L, Martin-Berra J. Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipuzcoa. *Archivos de Bronconeumología*, 1998, 34:23–27.
 135. Pena VS et al. Geographic variations in prevalence and under diagnosis of COPD: results of the IBERPOC multicentre epidemiological study. *Chest*, 2000, 118:981–989.
 136. Mueller RE et al. The prevalence of chronic bronchitis, chronic airway obstruction, and respiratory symptoms in a Colorado city. *American Review of Respiratory Diseases*, 1971, 103:209–228.
 137. Mannino DM et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey 1988–1994. *Archives of Internal Medicine*, 2000, 160:1683–1689.
 138. Cullen KJ et al. Chronic respiratory disease in a rural community. *The Lancet*, 1968, 2:657–660.

139. Menezes AM, Victora CG, Rigatto M. Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study. *Thorax*, 1994, 49:1217–1221.
140. Menezes AM, Victora CG, Rigatto M. Chronic bronchitis and the type of cigarette smoked. *International Journal of Epidemiology*, 1995, 24:95–99.
141. Littlejohns P, Ebrahim S, Anderson R. Prevalence and diagnosis of chronic respiratory symptoms in adults. *British Medical Journal*, 1989, 298:1556–1560.
142. Magnusson S, Gislason T. Chronic bronchitis in Icelandic males: prevalence, sleep disturbances and quality of life. *Scandinavian Journal of Primary Health Care*, 1999, 17:100–104.
143. Qureshi KA. Domestic smoke pollution and prevalence of chronic bronchitis/asthma in rural area of Kashmir. *Indian Journal of Chest Diseases and Allied Sciences*, 1994, 36:61–72.
144. Pandey RM. Prevalence of chronic bronchitis in a rural community of the Hill Region of Nepal. *Thorax*, 1984, 39:331–336.
145. Cookson JB, Mataka G. Prevalence of chronic bronchitis in Rhodesian Africans. *Thorax*, 1978, 33:328–334.
146. Higgins MW, Keller JB, Metzner HL. Smoking, socioeconomic status, and chronic respiratory disease. *American Review of Respiratory Diseases*, 1977, 116:403–410.
147. Menotti A et al. The relation of chronic diseases to all-cause mortality risk – the Seven Countries Study. *Annals of Internal Medicine*, 1997, 29:135–141.
148. Cerveri I et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. *European Respiratory Journal*, 2001, 18:85–92.
149. Chen Y, Breithaupt R, Muhajarine N. Occurrence of chronic obstructive pulmonary disease among Canadians and sex-related risk factors. *Journal of Clinical Epidemiology*, 2000, 53:755–761.
150. Lacasse Y, Brooks D, Goldstein RS. Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society. *Chest*, 1999, 116:306–313.
151. Meren M et al. Asthma, chronic bronchitis and respiratory symptoms among adults in Estonia according to a postal questionnaire. *Respiratory Medicine*, 2001, 95:954–964.
152. Pallasaho P et al. Increasing prevalence of asthma but not of chronic bronchitis in Finland? Report from the FinEss-Helsinki Study. *Respiratory Medicine*, 1999, 93:798–809.
153. Lai CK et al. Respiratory symptoms in elderly Chinese living in Hong Kong. *European Respiratory Journal*, 1995, 8:2055–2061.
154. Lundback B et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. *European Respiratory Journal*, 1991, 4:257–266.
155. Montnemery P et al. Prevalence of obstructive lung diseases and respiratory symptoms in Southern Sweden. *Respiratory Medicine*, 1998, 92:1337–1345.
156. Lebowitz MD, Knudson RJ, Burrows B. Tucson epidemiologic study of obstructive lung diseases. I: Methodology and prevalence of disease. *American Journal of Epidemiology*, 1975, 102:137–152.
157. Adams P, Hendershot G, Marano M. Current estimates from the National Health Interview Survey, 1996. *Vital Health Statistics*, 1999, 200:1–203.
158. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. *Respirology*, 2003, 8:192–198.
159. Yang G, et al. Smoking in China: findings of the 1996 National Prevalence Survey. *JAMA: The Journal of the American Medical Association*, 1999, 282:1247–1253.

160. Xu F et al. Prevalence of physician-diagnosed COPD and its association with smoking among urban and rural residents in regional mainland China. *Chest*, 2005, 128:2818–2823.
161. Jindal SK, Aggarwal AN, Gupta D. A review of population studies from India to estimate national burden of chronic obstructive pulmonary disease and its association with smoking. *Indian Journal of Chest Diseases and Allied Sciences*, 2001, 43:139–147.
162. Jindal SK et al. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. *Indian Journal of Chest Diseases and Allied Sciences*, 2006, 48:23–29.
163. Jindal SK et al. Tobacco smoking in India: prevalence, quit-rates and respiratory morbidity. *Indian Journal of Chest Diseases and Allied Sciences*, 2006, 48:37–42.
164. Buist SA et al. The Burden of Obstructive Lung Disease initiative (BOLD): Rationale and design. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 2005, 277–283.
165. Liu SM et al. Epidemiologic analysis of COPD in Guangdong province. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi / Chinese Journal of Medical Genetics*, 2005, 85:747–752.
166. Menezes AM et al. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in Sao Paulo, Brazil. *Cadernos de Saúde Pública*, 2005, 21:1565–1573.
167. Menezes AM, Victora CG, Perez-Padilla R. The Platino project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities. *BioMed Central Medical Research Methodology*, 2004, 4:15.
168. Menezes AM et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. *The Lancet*, 2005, 366:1875–1881.
169. Soriano JB et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. *Chest*, 2003, 124:474–481.
170. Zaher C et al. Smoking-related diseases: the importance of COPD. *International Journal of Tuberculosis and Lung Disease*, 2004, 8:1423–1428.
171. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. *European Respiratory Journal*, 2003, 22:809–814.
172. Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. *American Journal of Epidemiology*, 1991, 133:795–800.
173. He J et al. Major causes of death among men and women in China. *New England Journal of Medicine*, 2005, 353:1124–1134.
174. *Morbidity and mortality: 2004 chart book on cardiovascular, lung, and blood diseases*. National Institutes for Health, National Heart, Lung, and Blood Institute; 2004.
175. Jemal A et al. Trends in the leading causes of death in the United States, 1970–2002. *JAMA: The Journal of the American Medical Association*, 2005, 294:1255–1259.
176. *National Heart, Lung, and Blood Institute. Data Fact Sheet: Chronic Obstructive Pulmonary Disease, Vol. 2004*. Department of Health and Human Services, 2004.
177. Sin DD et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. *Thorax*, 2005, 60:992–997.
178. Murray J, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. *The Lancet*, 1997, 349:1269–1276.
179. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. *Respiratory Medicine*, 2005, 99:S11–S18.
180. ZuWallack RL, Haggerty MC, Jones P. Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. *The American Journal of the Medical Sciences*,

2004, 117: Suppl 12A, 49S–59S.

181. Doll H, Miravittles M. Health-related QoL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. *Pharmacoeconomics*, 2005, 23:345–363.
182. Yeo J, Karimova G, Bansal S. Co-morbidity in older patients with COPD – its impact on health service utilisation and quality of life, a community study. *Age and Ageing*, 2006, 35:33–37.
183. Schmier JK et al. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. *Quality of Life Research*, 2005, 14:329–347.
184. Pauwels R et al. COPD exacerbations: the importance of a standard definition. *Respiratory Medicine*, 2006, 98:99–107.
185. MacNee W. Acute exacerbations of COPD. *Swiss Medical Weekly*, 2003, 133 (17-18):247–257.
186. Dolan S, Varkey B. Prognostic factors in chronic obstructive pulmonary disease. *Current Opinion in Pulmonary Medicine*, 2005, 11:149–152.
187. Burney P et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. *European Respiratory Journal*, 2003, 43:1S–44S.
188. Enfermedad pulmonar obstructiva cronica. Magnitud del problema. Enfermedad pulmonar obstructiva cronica. *Conceptos Generales [General Concepts]*, 1992,57–65.
189. Hilleman DE et al. Pharmacoeconomic evaluation of COPD. *Chest*, 2000, 118:1278–1285.
190. Jacobson L et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. *Respiratory Medicine*, 2000, 94:247–255.
191. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. *Respiratory Medicine*, 2000, 94:204–213.
192. Rutten-van Molken MP, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. *Respiratory Medicine*, 1999, 93:779–787.
193. Dal-Negro R et al. Global outcomes in Lund Disease Study Group. Cost-of-illness of lung disease in the TriVento Region, Italy: the GOLD study. *Monaldi Archives of Chest Disease*, 2002, 57:3–9.
194. Jansson SA et al. Costs of COPD in Sweden according to disease severity. *Chest*, 2002, 122:1994–2002.
195. Miravittles M et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. *Chest*, 2003, 123:784–791.
196. Masa J et al. Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study. *Archivos de Bronconeumología*, 2004, 40:72–79.
197. Cotes C. Pharmacoeconomics and the burden of COPD. *Clinical Pulmonary Medicine*, 2005, 12:S19–S21.
198. Mapel DW et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. *Respiratory Medicine*, 2005, 99:1325–1333.
199. Prescott E, Lange P, Vestbo J. Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population. *Thorax*, 1997, 52:287–289.
200. Hansell AL et al. Validity and interpretation of mortality, health service and survey data on COPD and asthma in England. *European Respiratory Journal*, 2003, 21:279–286.
201. Watson L et al. Predictors of lung function and its decline in mild to moderate COPD in

- association with gender: Results from the Euroscop study. *Respiratory Medicine*, 2006, 100:746–753.
202. *WHO Mortality Database*. Geneva, World Health Organization, 2006.
 203. Kanner RE et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. *American Review of Respiratory Diseases*, 1994, 150:956–961.
 204. Chen Y, Horne SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. *American Review of Respiratory Diseases*, 1991, 143:1224–1230.
 205. Chapman K. Chronic obstructive pulmonary disease: are women more susceptible than men? *Clinics in Chest Medicine*, 2004, 25:331–341.
 206. Downs SH et al. Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study. *Respiratory Research*, 2005, 6:45.
 207. Dransfield MT et al. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. *Respiratory Medicine*, 2006, 100:1110–1116.
 208. Agusti AG. COPD, a multicomponent disease: implications for management. *Respiratory Medicine*, 2005, 99:670–682.
 209. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, 2005, 2:50–60.
 210. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. *European Respiratory Journal*, 2003, 46 (Suppl): 2–4.
 211. Kriegsman DM, Deeg DJ, Stalman WA. Comorbidity of somatic chronic diseases and decline in physical functioning: the Longitudinal Aging Study Amsterdam. *Journal of Clinical Epidemiology*, 2004, 57:55–56.
 212. Mikkelsen RL et al. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). *Nordic Journal of Psychiatry*, 2004, 58:65–70.
 213. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity – a common inflammatory phenotype? *Respiratory Research*, 2006, 70.
 214. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. *Proceedings of the American Thoracic Society*, 2005, 2:8–11.
 215. Lyness JM et al. The relationship of medical comorbidity and depression in older, primary care patients. *Psychosomatics*, 2006, 47:435–439.
 216. Bolton CE et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, 2004, 170:1286–1293.
 217. Berger JS et al. Comparison of three-year outcomes in blacks versus whites with coronary heart disease following percutaneous coronary intervention. *American Journal of Cardiology*, 2004, 94:647–649.
 218. Kjoller E et al. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. *European Journal of Heart Failure*, 2004, 6:71–77.
 219. Sidney S et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser permanente medical care program. *Chest*, 2005, 128:2068–2075.
 220. Braunstein JB et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. *Journal of the American College of Cardiology*, 2003, 42:1226–1233.
 221. Petty TL. Are COPD and lung cancer two manifestations of the same disease? *Chest*,

2005, 128:1895–1897.

222. Mannino DM et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. *Archives of Internal Medicine*, 2003, 163:1475–1480.
223. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, 2004, 140:740–753.
224. Deegan PC, McNicholas WT. Pathophysiology of obstructive sleep apnoea. *European Respiratory Journal*, 1995, 8:1161–1178.
225. Young T et al. The occurrence of sleep-disordered breathing among middle-aged adults. *The New England Journal of Medicine*, 1993, 328:1230–1235.
226. Duran J et al. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. *American Journal of Respiratory and Critical Care Medicine*, 2001, 163:685–689.
227. Bixler EO et al. Effects of age on sleep apnea in men: I. Prevalence and severity. *American Journal of Respiratory and Critical Care Medicine*, 1998, 157:144–148.
228. Stradling JR, Crosby JH. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. *Thorax*, 1991, 46:85–90.
229. Bearpark H et al. Snoring and sleep apnea. A population study in Australian men. *American Journal of Respiratory and Critical Care Medicine*, 1995, 151:1459–1465.
230. Ip MS et al. A community study of sleep disorder breathing in middle-aged Chinese men in Hong Kong. *Chest*, 2001, 119:62–69.
231. Ip MS et al. A community study of sleep-disordered breathing in middle-aged Chinese women in Hong Kong: prevalence and gender differences. *Chest*, 2004, 125:127–134.
232. Cistulli PA, Sullivan CE. Sleep apnea in Marfan's syndrome. Increased upper airway collapsibility during sleep. *Chest*, 1995, 108:631–635.
233. Ancoli-Israel S et al. Sleep-disordered breathing in community-dwelling elderly. *Sleep*, 1991, 14:486–495.
234. Cohen-Zion M et al. Changes in cognitive function associated with sleep disordered breathing in older people. *Journal of the American Geriatrics Society*, 2001, 49:1622–1627.
235. Gislason T, Benediktsdottir B. Snoring, apneic episodes, and nocturnal hypoxemia among children 6 months to 6 years old. An epidemiologic study of lower limit of prevalence. *Chest*, 1995, 107:963–966.
236. Marcus CL. Sleep-disordered breathing in children. *American Journal of Respiratory and Critical Care Medicine*, 2001, 164:16–30.
237. Kiely JL, McNicholas WT. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. *European Respiratory Journal*, 2000, 16:128–133.
238. Nieto FJ et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA: The Journal of The American Medical Association*, 2000, 283:1829–1836.
239. Peppard PE et al. Prospective study of the association between sleep-disordered breathing and hypertension. *New England Journal of Medicine*, 2000, 342:1378–1384.
240. Shahar E et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. *American Journal of Respiratory and Critical Care Medicine*, 2001, 163:19–25.
241. Peker Y et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. *American Journal of Respiratory and Critical Care Medicine*, 2002, 166:159–165.

242. Doherty LS et al. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. *Chest*, 2005, 127:2076–2084.
243. Marin JM et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *The Lancet*, 2005, 365:1046–1053.
244. Ronald J et al. Healthcare utilization in the 10 years prior to diagnosis in obstructive sleep apnea syndrome patients. *Sleep*, 1999, 22:225–229.
245. Otake K et al. Cardiovascular medication use in patients with undiagnosed obstructive sleep apnea. *Thorax*, 2002, 57:417–422.
246. Bahammam A et al. Healthcare utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. *Sleep*, 1999, 22:740–748.
247. Kapur V et al. The medical cost of undiagnosed sleep apnea. *Sleep*, 1999, 22:749–756.
248. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. *New England Journal of Medicine*, 1999, 340:881–883.
249. Krieger J et al. Public health and medicolegal implications of sleep apnoea. *European Respiratory Journal*, 2002, 20:1594–1609.
250. George CFP. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. *Thorax*, 2001, 56:508–512.
251. Report of a Task Force of the American Academy of Sleep Medicine. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. *Sleep*, 1999, 22:667–689.
252. Executive summary on the systematic review and practice parameters for portable monitoring in the investigation of suspected sleep apnea in adults. *American Journal of Respiratory and Critical Care Medicine*, 2004, 169:1160–1163.
253. Cost justification for diagnosis and treatment of obstructive sleep apnea. *Sleep*, 2000, 23:1017–1018.
254. Engleman HM, Douglas NJ. Sleep 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. *Thorax*, 2004, 59:618–622.
255. Naegele B et al. Deficits of cognitive executive functions in patients with sleep apnea syndrome. *Sleep*, 1995, 18:43–52.
256. Arzt M et al. Association of sleep-disordered breathing and the occurrence of stroke. *American Journal of Respiratory and Critical Care Medicine*, 2005, 172:1447–1451.
257. Becker HF et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. *Circulation*, 2003, 107:68–73.
258. Simonneau G et al. Clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology*, 2004, 43 (12 Suppl S):5S–12S.
259. Humbert M et al. Risk factors for pulmonary arterial hypertension. *Clinics in Chest Medicine*, 2001, 22:459–475.
260. Naeije R. Pulmonary hypertension and right heart failure in COPD. *Monaldi Archives of Chest Disease*, 2003, 59:250–253.
261. Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. *Proceedings of the American Thoracic Society*, 2005, 2:12–19.
262. Maggiorini M, Leon-Velarde F. High-altitude pulmonary hypertension: a pathophysiological entity to different diseases. *European Respiratory Journal*, 2003, 22:1019–1025.
263. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary

- arterial hypertension. *Annals of Internal Medicine*, 2005, 143:282–292.
264. Bethlem EP, Schettino G, Carvalho CR. Pulmonary schistosomiasis. *Current Opinion in Pulmonary Medicine*, 1997, 3:361–365.
265. Laosebikan AO, Thomson SR, Naidoo NM. Schistosomal portal hypertension. *Journal of the American College of Surgeons*, 2005, 200:795–806.
266. Lambertucci JR et al. *Schistosoma mansoni*: assessment of morbidity before and after control. *Acta Tropica*, 2000, 77:101–109.
267. Engels D et al. The global epidemiological situation of schistosomiasis and new approaches to control and research. *Acta Tropica*, 2002, 82:139–146.
268. Gladwin MT et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *New England Journal of Medicine*, 2004, 350:886–895.
269. Valencia-Flores M et al. Prevalence of pulmonary hypertension and its association with respiratory disturbances in obese patients living at moderately high altitude. *International Journal of Obesity and Related Metabolic Disorders*, 2004, 28:1174–1180.
270. *Fuel for life. Household Energy and Health*. Geneva, World Health Organization, 2006.
271. Bonita R, Howe AL. Older women in an aging world: achieving health across the life course. *World Health Statistics Quarterly*, 1996, 49:134–141.
272. Rehfuess E, Mehta S, Prüss-Ustün A. Assessing Household Solid Fuel Use: Multiple Implications for the Millennium Development Goals. *Environmental Health Perspectives*, 2006, 114:373-378.
273. Warren CW, et al. Global Tobacco Surveillance System (GTSS) collaborative group. Patterns of global tobacco use in young people and implications for future chronic disease burden in adults. *The Lancet*, 2006, 749–753.
274. Esson K, Leeder S. *The Millennium Development Goals and Tobacco Control. An opportunity for global partnership*. 2004. Geneva, World Health Organization.
275. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. *The Lancet*, 2003, 362:847–852.
276. *The World Health Report 2003: shaping the future*. Geneva, World Health Organization, 2003.
277. Lopez AD, Collishaw N, Silva V. A descriptive model of the cigarette epidemic in developed countries. *Tobacco Control*, 1994, 3:242–247.
278. Peto R et al. Mortality from smoking worldwide. *British Medical Bulletin*, 1996, 52:12–21.
279. *Curbing the epidemic: governments and the economics of tobacco control*. 1999. Washington DC, World Bank.
280. Gupta PC et al. Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay Cohort Study. *International Journal of Epidemiology*, 2005.
281. *Tobacco: deadly in any form or disguise*. Geneva, World Health Organization, 2006.
282. Gupta PC, Mehta HC. Cohort study of all-cause mortality among tobacco users in Mumbai, India. *Bulletin of the World Health Organization*, 2000, 78:877–883.
283. Neufeld KJ et al. Regular use of alcohol and tobacco in India and its association with age, gender, and poverty. *Drug and Alcohol Dependence*, 2005, 77:283–291.
284. *Report on Carcinogens, Eleventh Edition*. Washington, DC, United States of America Department of Health and Human Services, 2005.
285. Janson C. The effect of passive smoking on respiratory health in children and adults. *International Journal of Tuberculosis and Lung Diseases*, 2004, 8:510–516.

286. Johnson KC. Accumulating evidence on passive and active smoking and breast cancer risk. *International Journal of Cancer*, 2005, 117:619–628.
287. Bonita R et al. Passive smoking as well as active smoking increases the risk of acute stroke. *Tobacco Control*, 1999, 8:156–160.
288. *Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant, SRP Approved Version, 24 June 2005. Health Effects*. California Environmental Protection Agency (<http://www.arb.ca.gov/toxics/ats/finalreport/finalreport.html>, accessed 4 January 2007).
289. *The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of The Surgeon General*. Atlanta, United States of America Department of Health and Human Services, Centers for Diseases Control and Prevention (<http://www.cdc.gov/tobacco/sgr/sgr2006/index.html>, accessed 4 January 2007).
290. Ezzati M et al. Rethinking the “diseases of affluence” paradigm: global patterns of nutritional risks in relation to economic development. *PLoS Medicine*, 2005, 2:e133.
291. Sumer H. et al. The association of biomass fuel combustion on pulmonary function tests in the adult population of Mid-Anatolia. *Sozial- und Präventivmedizin/Social and Preventive Medicine*, 2004, 49:247–253.
292. Viegi G et al. Indoor air pollution and airway disease. *The International Journal of Tuberculosis and Lung Diseases*, 2004, 8:1401–1415.
293. Kunzli N. Biomass fuel makes lungs a decade older – time to take action. *Sozial- und Präventivmedizin/Social and Preventive Medicine*, 2004, 49:233–234.
294. Ekici A et al. Obstructive airway diseases in women exposed to biomass smoke. *Environmental Research*, 2001, 99:93–98.
295. Ezzati M, Kammen D. Indoor air pollution from biomass combustion and acute respiratory infections in Kenya: an exposure–response study. *The Lancet*, 2001, 358:619–624.
296. Mishra V. Indoor air pollution from biomass combustion and acute respiratory illness in preschool age children in Zimbabwe. *International Journal of Epidemiology*, 2003, 32:847–853.
297. Al-Khatib I et al. Impact of housing conditions on the health of the people at al-Ama’ri refugee camp in the West Bank of Palestine. *International Journal of Environmental Health Research*, 2003, 13:315–326.
298. Kiraz K et al. Chronic pulmonary disease in rural women exposed to biomass fumes. *Clinical and Investigative Medicine*, 2003, 26:243–248.
299. Smith KR et al. Indoor air pollution in developing countries and acute lower respiratory infections in children. *Thorax*, 2000, 55:518–532.
300. Shrestha IL, Shrestha SL. Indoor air pollution from biomass fuels and respiratory health of the exposed population in Nepalese households. *International Journal of Occupational and Environmental Health*, 2005, 11:150–160.
301. Golshan M, Faghihi M, Marandi MM. Indoor women jobs and pulmonary risks in rural areas of Isfahan, Iran, 2000. *Respiratory Medicine*, 2002, 6:127.
302. Saha A et al. Pulmonary function and fuel use: a population survey. *Respiratory Research*, 2005, 6:127.
303. Bailis R, Ezzati M, Kammen D. Mortality and greenhouse gas impacts of biomass and petroleum energy futures in Africa. *Science*, 2005, 308:98–103.
304. Orozco-Levi M et al. Wood smoke exposure and risk of chronic obstructive pulmonary disease. *European Respiratory Journal*, 2006, 27:542–546.
305. *Air Quality Guidelines: Global Update 2005*. Geneva, World Health Organization, 2006.
306. What constitutes an adverse health effect of air pollution? Official statement of the

- American Thoracic Society. *American Journal of Respiratory and Critical Care Medicine*, 2000, 161:665–673.
307. Hoek G et al. Association between mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study. *The Lancet*, 2002, 360:1203–1209.
308. Pope DW, Dockery DW. Acute health effects of PM10 pollution on symptomatic and asymptomatic children. *American Review of Respiratory Diseases*, 1992, 145:1123–1128.
309. Gauderman WJ et al. The effect of air pollution on lung development from 10 to 18 years of age. *New England Journal of Medicine*, 2004, 351:1057–1067.
310. Yang Q et al. Effect of short-term exposure to low levels of gaseous pollutants on chronic obstructive pulmonary disease hospitalizations. *Environmental Research*, 2005, 99:99–105.
311. Zemp E et al. Long-term ambient air pollution and respiratory symptoms in adults (SAPALDIA study). The SAPALDIA Team. *American Journal of Respiratory and Critical Care Medicine*, 1999, 159:1257–1266.
312. Trasande L, Thurston GD. The role of air pollution in asthma and other pediatric morbidities. *Journal of Allergy and Clinical Immunology*, 2005, 115:689–699.
313. *GINA Report, Global strategy for asthma management and prevention (Revised 2005)*. Global Initiative for Asthma, 2005.
314. Tager IB et al. Chronic exposure to ambient ozone and lung function in young adults. *Epidemiology*, 2005, 16:751–759.
315. Cohen AJ et al. The global burden of disease due to outdoor air pollution. *Journal of Toxicology and Environmental Health*, 2005, 68:1301–1307.
316. Cookson W, Moffatt M. Making sense of asthma genes. *New England Journal of Medicine*, 2004, 351:1794–1796.
317. Wong GW et al. Factors associated with difference in prevalence of asthma in children from three cities in China: multicentre epidemiological survey. *British Medical Journal*, 2004, 329:486.
318. Yssel H et al. The role of IgE in asthma. *Clinical and Experimental Allergy*, 1998, 28:104–109.
319. Erwin EA, Platts-Mills TA. Allergens. *Immunology and Allergy Clinics of North America*, 2005, 25:1–14.
320. Sunyer J et al. Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study. *Journal of Allergy and Clinical Immunology*, 2004, 114:1033–1039.
321. Camara AA et al. Risk factors for wheezing in a subtropical environment: role of respiratory viruses and allergen sensitization. *Journal of Allergy and Clinical Immunology*, 2004, 113:551–557.
322. Addo-Yobo EO et al. Risk factors for asthma in urban Ghana. *Journal of Allergy and Clinical Immunology*, 2001, 108:363–368.
323. Ndiaye M, Bousquet J. Allergies and parasitoses in sub-Saharan Africa. *Clinical Reviews in Allergy & Immunology*, 2004, 26:105–113.
324. Yazdanbakhsh M, Wahyuni S. The role of helminth infections in protection from atopic disorders. *Current Opinion in Allergy and Clinical Immunology*, 2005, 5:386–391.
325. Rosenstreich DL et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. *New England Journal of Medicine*, 1997, 336:1356–1363.
326. *Six network meeting of the WHO Collaborating Centres in Occupational Health. Summary report*. 2003. Geneva, World Health Organization.

327. Nelson DI et al. The global burden of selected occupational diseases and injury risks: Methodology and summary. *American Journal of Industrial Medicine*, 2005, 48:400–418.
328. Balmes J et al. American Thoracic Society Statement: occupational contribution to the burden of airway disease. *American Journal of Respiratory and Critical Care Medicine*, 2003, 167:787–797.
329. Gamble JF, Hessel PA, Nicolich M. Relationship between silicosis and lung function. *Scandinavian Journal of Work, Environment & Health*, 2004, 30:5–20.
330. ILO Encyclopedia of Occupational Health and Safety. Geneva, International Labour Organization, 1997.
331. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. *Lung Cancer*, 2005, 49 Suppl 1:S3–S8.
332. Hessel PA, Gamble JF, McDonald JC. Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence. *Thorax*, 2005, 60:433–436.
333. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *The Lancet*, 2005, 366:397–408.
334. Davies JC. Silicosis and tuberculosis among South African goldminers –an overview of recent studies and current issues. *South African Medical Journal*, 2001, 91:562–566.
335. Hessel PA, Gamble JF, Nicolich M. Relationship between silicosis and smoking. *Scandinavian Journal of Work, Environment & Health*, 2003, 29:329–336.
336. Vandenas O, Toren K, Blanc PD. Health and socioeconomic impact of work-related asthma. *European Respiratory Journal*, 2003, 22:689–697.
337. Malo JL et al. Occupational asthma. *Current Opinion in Pulmonary Medicine*, 2004, 10:57–61.
338. Mapp CE et al. Occupational asthma. *American Journal of Respiratory and Critical Care Medicine*, 2005, 172:280–305.
339. Trupin L et al. The occupational burden of chronic obstructive pulmonary disease. *European Respiratory Journal*, 2003, 22:462–469.
340. Driscoll T et al. The global burden of non-malignant respiratory disease due to occupational airborne exposures. *American Journal of Industrial Medicine*, 2005, 48:432–445.
341. Liss GM et al. Hospitalization among workers compensated for occupational asthma. *American Journal of Respiratory and Critical Care Medicine*, 2000, 162:112–118.
342. Loewenson R. Globalization and occupational health: a perspective from southern Africa. *Bulletin of the World Health Organization*, 2001, 79:863–868.
343. Romieu I, Trenga C. Diet and obstructive lung diseases. *Epidemiologic Reviews*, 2001, 23:268–287.
344. *Diet, Nutrition and Prevention of Chronic Diseases. Report of a joint WHO/FAO Expert Consultation*. Geneva, World Health Organization, 2003 (WHO Technical Report Series, No. 916).
345. Ram FS, Ardern KD. Dietary salt reduction or exclusion for allergic asthma. *Cochrane database of systematic reviews*, 2004, 3.
346. McKeever TM, Britton J. Diet and asthma. *American Journal of Respiratory and Critical Care Medicine*, 2004, 170:725–729.
347. Woods R, Thien F, Abramson M. Dietary marine fatty acids (fish oil) for asthma in adults and children. *Cochrane database of systematic reviews*, 2002, 3.
348. Forastiere F et al. Consumption of fresh fruit rich in vitamin C and wheezing symptoms in children. SIDRIA Collaborative Group, Italy (Italian Studies on Respiratory Disorders in

- Children and the Environment). *Thorax*, 2000, 55:283–288.
349. Antova T et al. Nutrition and respiratory health in children in six Central and Eastern European countries. *Thorax*, 2003, 58:231–236.
350. Kelly Y, Sacker A, Marmot M. Nutrition and respiratory health in adults: findings from the health survey for Scotland. *European Respiratory Journal*, 2003, 21:664–671.
351. Ram FS, Rowe BH, Kaur B. Vitamin C supplementation for asthma. *Cochrane database of systematic reviews*, 2004, 3.
352. Bergeron C, Boulet LP, Hamid Q. Obesity, allergy and immunology. *Journal of Allergy and Clinical Immunology*, 2005, 115:1102–1104.
353. Hallstrand TS et al. Genetic pleiotropy between asthma and obesity in a community-based sample of twins. *Journal of Allergy and Clinical Immunology*, 2005, 116:1235–1241.
354. Braback L, Hjern A, Rasmussen F. Body mass index, asthma and allergic rhinoconjunctivitis in Swedish conscripts – a national cohort study over three decades. *Respiratory Medicine*, 2005, 99:1010–1014.
355. Mannino DM et al. Boys with high body masses have an increased risk of developing asthma: findings from the National Longitudinal Survey of Youth (NLSY). *International Journal of Obesity*, 2006, 30:6–13.
356. Kim S, Camargo CAJ. Sex-race differences in the relationship between obesity and asthma: the behavioral risk factor surveillance system. *Annals of Epidemiology*, 2003, 13:666–673.
357. Perez-Padilla R et al. Obesity among children residing in Mexico City and its impact on lung function: a comparison with Mexican-Americans. *Archives of Medical Research*, 2006, 37:165–171.
358. Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. *Archives of Internal Medicine*, 2002, 162:1477–1481.
359. Lavoie KL et al. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. *Respiratory Medicine*, 2006, 100:648–657.
360. Saint-Pierre P et al. Are overweight asthmatics more difficult to control? *Allergy*, 2006, 61:79–84.
361. Cheng J et al. Calorie controlled diet for chronic asthma. *Cochrane database of systematic reviews*, 2005, 3.
362. *Global Strategy on diet, physical activity and health*. Geneva, World Health Organization, 2004.
363. Prescott E et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. *European Respiratory Journal*, 2002, 20:539–544.
364. Celli BR et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *New England Journal of Medicine*, 2004, 350:1005–1012.
365. Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. *European Respiratory Journal*, 2003, Suppl November:81s–86s.
366. Calvert J, Burney P. Effect of body mass on exercise-induced bronchospasm and atopy in African children. *Journal of Allergy and Clinical Immunology*, 2005, 116:773–779.
367. Wesley AG. Prolonged after-effects of pneumonia in children. *South African Medical Journal*, 1991, 79:73–76.
368. Sethi GR, Batra V. Bronchiectasis: causes and management. *Indian Journal of Pediatrics*, 2000, 67:133–139.

369. Tiendrebeogo H et al. Cent un cas d'aspergillose pulmonaires en Côte d'Ivoire. *Médecine Tropicale [Tropical Medicine]*, 1982, 42:47–52.
370. Mushegera C, Mbuyi-Muamba JM, Kabemba MJ. Indications and results of pleuropulmonary decortications in the university hospital of Kinshasa. *Acta Chirurgica Belgica*, 1996, 96:217–222.
371. Souilamas R et al. Surgical treatment of active and sequelar forms of pulmonary tuberculosis. *Annals of Thoracic Surgery*, 2001, 71:443–447.
372. Paoletti P et al. Effects of childhood and adolescence-adulthood respiratory infections in a general population. *European Respiratory Journal*, 1989, 2:428–436.
373. Martinez FD. Toward asthma prevention - does all that really matters happen before we learn to read? *New England Journal of Medicine*, 2003, 349:1473–1475.
374. Nelson EA, Olukoya A, Scherpbier RW. Towards an integrated approach to lung health in adolescents in developing countries. *Annals of Tropical Paediatrics*, 2004, 24:117–131.
375. ten Asbroek AH et al. Implementing global knowledge in local practice: a WHO lung health initiative in Nepal. *Health Policy Plan*, 2005, 20:290–301.
376. Veron LJ et al. DOTS expansion: will we reach the 2005 targets? *International Journal of Tuberculosis and Lung Diseases*, 2004, 8:139–146.
377. Armstrong T, Bonita R. Capacity building for an integrated noncommunicable disease risk factor surveillance system in developing countries. *Ethnicity & Disease*, 2003, 13:S13–S18.
378. Burney PG et al. The European Community Respiratory Health Survey. *European Respiratory Journal*, 1994, 7:954–960.
379. Pekkanen J et al. Operational definitions of asthma in studies on its aetiology. *European Respiratory Journal*, 2005, 26:28–35.
380. Pistelli F et al. Usefulness of a compendium of respiratory standard questionnaires for adults (CORSQ). *European Respiratory Review*, 2001, 11:98–102.
381. Pistelli F et al. Appendix 3: Compendium of respiratory standard questionnaires for adults (CORSQ). *European Respiratory Review*, 2001, 11:118–143.
382. Strong KL, Bonita R. Investing in surveillance: a fundamental tool of public health. *Sozialund Präventivmedizin/Social and Preventive Medicine*, 2004, 49:269–275.
383. Piau J-P et al. Questionnaire on health systems and national resources for control of respiratory health in low-income countries. *International Journal of Tuberculosis and Lung Diseases*, 2005, 9:1403–1408.
384. Asher MI et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *European Respiratory Journal*, 1995, 8:483–491.
385. Yach D et al. The global burden of chronic diseases: overcoming impediments to prevention and control. *JAMA: The Journal of the American Medical Association*, 2004, 291:2616–2622.
386. Tang K, Beaglehole R, O'Byrne D. Policy and partnership for health promotion addressing the determinants of health. *Bulletin of the World Health Organization*, 2005, 83:884–885.
387. Kunzli N. The public health relevance of air pollution abatement. *European Respiratory Journal*, 2002, 20:198–209.
388. Rodgers A et al. Distribution of major health risks: findings from the Global Burden of Disease study. *PLoS Medicine*, 2004, 1:e27.
389. Last J. *A Dictionary of Epidemiology*. New York, Oxford University Press, 1995.
390. Borland R et al. Determinants and consequences of smoke-free homes: findings from the International Tobacco Control (ITC) Four Country Survey. *Tobacco Control*, 2006, 15 (suppl 3):71–75.

391. Merom D, Rissel C. Factors associated with smoke free homes in NSW: results from the 1998 NSW health survey. *Australian and New Zealand Journal of Public Health*, 2001, 25:339-345.
392. Borland R et al. Trends in environmental tobacco smoke restrictions in the home in Victoria, Australia. *Tobacco Control*, 1999, 8:226-271.
393. *Protection from exposure to second-hand tobacco smoke. Policy recommendations*. Geneva, World Health Organization, 2007.
394. *Ottawa Charter for Health Promotion*. Geneva, World Health Organization, 1986.
395. Wipfli H et al. Achieving the Framework Convention on Tobacco Control's potential by investing in national capacity. *Tobacco Control*, 2004, 13:433-437.
396. Asher MI et al. World Allergy Organization guidelines for prevention of allergy and allergic asthma. *International Archives of Allergy and Immunology*, 2004, 135:83-92.
397. *Prevention of Allergy and Allergic Asthma*. Geneva, World Health Organization, 2003.
398. Hublet A et al. Smoking in young people with asthma. *Journal of Public Health (Oxf)* 2007 (Aug 4); Epub ahead of print.
399. Bruce N et al. Impact of improved stoves, house construction and child location on levels of indoor air pollution exposure in young Guatemalan children. *Journal of Exposure Analysis and Environmental Epidemiology*, 2004, 14:S26-S33.
400. Chapman RS et al. Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study. *British Medical Journal*, 2005, 331:1050-1055.
401. El Tayeb Muneer S, Mukhtar Mohamed el W. Adoption of biomass improved cookstoves in a patriarchal society: an example from Sudan. *Science of the Total Environment*, 2003, 307:259-266.
402. Ezzati M, Kammen DM. The health impacts of exposure to indoor air pollution from solid fuels in developing countries: knowledge, gaps, and data needs. *Environmental Health Perspectives*, 2002, 110:1057-1068.
403. Mannan M. Women targeted and women negated. An aspect of the environmental movement in Bangladesh. *Development in practice*, 1996, 6:113-120.
404. Schei M, et al. Childhood asthma and indoor woodsmoke from cooking in Guatemala. *Journal of Exposure Analysis and Environmental Epidemiology*, 2004, 14:S110-S117.
405. Jones CA, Holloway JA, Warner JO. Does atopic disease start in foetal life? *Allergy*, 2000, 55:2-10.
406. Bousquet J et al. Epigenetic inheritance of fetal genes in allergic asthma. *Allergy*, 2004, 59:138-147.
407. Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA²LEN). *Allergy*, 2005, 60:1112-1115.
408. Morgan WJ et al. Results of a home-based environmental intervention among urban children with asthma. *New England Journal of Medicine*, 2004, 351:1068-1080.
409. *American Conference of Governmental and Industrial Hygienists (ACGIH). Threshold Limit Values for Chemical Substances and Physical Agents & Biological Exposure Indices* (<http://www.acgih.org>, accessed 5 May 2007).
410. Malo JL et al. Natural history of occupational asthma: relevance of type of agent and other factors in the rate of development of symptoms in affected subjects. *Journal of Allergy and Clinical Immunology*, 1992, 90:937-944.
411. Newman Taylor A.J., et al. BOHRF guidelines for occupational asthma. *Thorax*, 2005, 60:364-366.

412. Bernstein I, Storms W. Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. *Annals of Allergy, Asthma and Immunology*, 1995, 75:543-625.
413. Li J et al. Algorithm for the diagnosis and management of asthma: a practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. *Annals of Allergy, Asthma and Immunology*, 1998, 81:415-420.
414. Dykewicz M et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. *Annals of Allergy, Asthma and Immunology*, 1998, 81:478-518.
415. Spector S et al. Symptom severity assessment of allergic rhinitis: part 1. *Annals of Allergy, Asthma and Immunology*, 2003, 91:105-114.
416. Brusasco V, Crapo R, Viegi G. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. *European Respiratory Journal*, 2005, 26:1-2.
417. Macintyre N et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *European Respiratory Journal*, 2005, 26:720-735.
418. Miller MR, Dickinson SA, Hickings DJ. The accuracy of portable peak flow meters. *Thorax*, 1992, 47:904-909.
419. Miller MR et al. Standardisation of spirometry. *European Respiratory Journal*, 2005, 26:319-338.
420. Pellegrino R et al. Interpretative strategies for lung function tests. *European Respiratory Journal*, 2005, 26:948-968.
421. Warner JO et al. Standardisation of the measurement of lung volumes. *European Respiratory Journal*, 2005, 26:511-522.
422. Dreborg S et al. Skin tests used in Type I allergy testing. Position Paper of the European Academy of Allergology and Clinical Immunology. *Allergy*, 1988, 44:1-69.
423. Halbert R, Isonaka S. International Primary Care Respiratory Group (IPCRG) Guidelines: Integrating Diagnostic Guidelines for Managing Respiratory Diseases in Primary Care. *Primary Care Respiratory Journal*, 2006, 15:13-19.
424. Levy M et al. International Primary Care Respiratory Group (IPCRG) Guidelines: Diagnosis of Respiratory Diseases in Primary Care. *Primary Care Respiratory Journal*, 2006, 15:i20-i34.
425. Mohangoo AD et al. Prevalence estimates of asthma or COPD from a health interview survey and from general practitioner registration: what's the difference? *European Journal of Public Health*, 2006, 16:101-105.
426. Schneider D, Freeman NC, McGarvey P. Asthma and respiratory dysfunction among urban, primarily Hispanic school children. *Archives of Environmental Health*, 2004, 59:4-13.
427. Wilt TJ et al. Use of Spirometry for Case Finding, Diagnosis, and Management of Chronic Obstructive Pulmonary Disease (COPD). *Evidence report/technology assessment (Summary)*, 2005, 121:1-7.
428. Williams SG et al. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. *MMWR Recommendations and Reports*, 2003, 52:1-8.
429. Montnemery P et al. Accuracy of a first diagnosis of asthma in primary health care. *Journal of Family Practice*, 2002, 19:365-368.
430. Rabe KF et al. Worldwide severity and control of asthma in children and adults: The global asthma insights and reality surveys. *Journal of Allergy and Clinical Immunology*, 2004, 114:40-47.

431. O'Dowd LC et al. Attitudes of physicians towards objective measures of airway function in asthma. *American Journal of the Medical Sciences*, 2003, 114:391–396.
432. Yu IT, Wong TW, Li W. Using child reported respiratory symptoms to diagnose asthma in the community. *Archives of Disease in Childhood*, 2004, 89:544–548.
433. Thiadens HA et al. Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study. *British Medical Journal*, 1998, 316:1286–1290.
434. Soriano JB et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. *European Journal of Epidemiology*, 2001, 17:1075–1080.
435. Tinkelman DG et al. Symptom-Based Questionnaire for Differentiating COPD and Asthma. *Respiration*, 2006, 73:296–305.
436. Roche N et al. Clinical practice guidelines: medical follow-up of patients with asthma - adults and adolescents. *Respiratory Medicine*, 2005, 99:793–815.
437. Boulet LP et al. Evaluation of asthma control by physicians and patients: comparison with current guidelines. *Canadian Respiratory Journal*, 2002, 9:417–423.
438. Nathan RA et al. Development of the asthma control test: a survey for assessing asthma control. *Journal of Allergy and Clinical Immunology*, 2004, 113:59–65.
439. Juniper EF et al. Measuring asthma control. Clinic questionnaire or daily diary? *American Journal of Respiratory and Critical Care Medicine*, 2000, 162:1330–1334.
440. Juniper EF et al. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. *Respiratory Medicine*, 2006, 100:616–621.
441. Gibson PG et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. *Clinical & Experimental Allergy*, 1992, 22:525–532.
442. Freeman D et al. Questions for COPD diagnostic screening in a primary care setting. *Respiratory Medicine*, 2005, 99:1311–1318.
443. Beeh KM et al. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. *Respiratory Medicine*, 2004, 98:591–597.
444. Schayck CV et al. Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting. *Respirology*, 2005, 10:323–333.
445. Price DB et al. COPD Questionnaire Study Group. Scoring system and clinical application of COPD diagnostic questionnaires. *Chest*, 2006, 129:1531–1539.
446. Sprenkle MD et al. The Veterans Short Form 36 questionnaire is predictive of mortality and health-care utilization in a population of veterans with a self-reported diagnosis of asthma or COPD. *Chest*, 2004, 126:81–89.
447. van Schayck CP, Chavannes NH. Detection of asthma and chronic obstructive pulmonary disease in primary care. *European Respiratory Journal*, 2003, 39:16s–22s.
448. *Global initiative for scaling up management of chronic diseases, Report of a WHO Meeting, Cairo, Egypt, 11-13 December 2005*. Geneva, World Health Organization, 2005.
449. *Practical Approach to Lung Health, A primary health care strategy for the integrated management of respiratory conditions in people of five years of age and over*. Geneva, World Health Organization, 2005.
450. Haahtela T, Laitinen LA. Asthma programme in Finland 1994-2004. Report of a Working Group. *Clinical & Experimental Allergy*, 1996, 26 (suppl):1–24.
451. *Programme d'actions, de prévention et de prise en charge de l'asthme. 2002-2005*. (<http://www.sante.gouv.fr>, accessed 28 Nov 2005).

452. *British guideline on the management of asthma. Thorax*, 2003, 58:i1–i94.
453. Miller MR et al. Severity assessment in asthma: An evolving concept. *Journal of Allergy and Clinical Immunology*, 2005, 116:990–995.
454. *National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 2: Guidelines for the diagnosis and management of asthma- Clinical Practice Guidelines*. Bethesda, United States, National Heart, Lung and Blood Institute, 1997.
455. *National Asthma Education and Prevention Program (NAEPP), Expert Panel Report: Guidelines for the diagnosis and management of asthma- Update on selected topics*. Bethesda, United States, National Heart, Lung and Blood Institute, 2002.
456. Bousquet J, Van Cauwenberge P. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. *Allergy*, 2004, 59:373–387.
457. van Schayck CP et al. The IPCRG Guidelines: Developing guidelines for managing chronic respiratory diseases in primary care. *Primary Care Respiratory Journal*, 2006, 15:1–4.
458. O'Byrne P. Asthma Management Guidelines: The Issue of Implementation. *Primary Care Respiratory Journal*, 2006, 15:5–6.
459. Price DB et al. International Primary Care Respiratory Group (IPCRG) guidelines: Management of allergic rhinitis. *Primary Care Respiratory Journal*, 2006, 15:20–34.
460. Bousquet J, Godard P, Grouse L. Global integrated guidelines are needed for respiratory diseases. *Primary Care Respiratory Journal*, 2006, 15:10–12.
461. van-den-Molen T et al. International Primary Care Respiratory Group (IPCRG) Guidelines: Management of Asthma. *Primary Care Respiratory Journal*, 2006, 15:35–47.
462. Higgins BW, Douglas JG. The new BTS/SIGN asthma guidelines: where evidence leads the way. *Thorax*, 2003, 58:98–99.
463. Shivbalan S, Balasubramanian S, Anandnathan K. What do parents of asthmatic children know about asthma?: An Indian perspective. *Indian Journal of Chest Diseases and Allied Sciences*, 2005, 47:81–87.
464. Anderson EW et al. Schools' capacity to help low-income, minority children to manage asthma. *Journal of School Nursing*, 2005, 21:236–242.
465. Henry RL, et al. Randomized controlled trial of a teacher-led asthma education program. *Pediatric pulmonology*, 2004, 38:434–442.
466. Pastore DR, Techow B. Adolescent school-based health care: a description of two sites in their 20th year of service. *Mount Sinai Journal of Medicine*, 2004, 71:191–196.
467. *Global strategy for asthma management and prevention. WHO/NHLBI workshop report*. National Institutes of Health, National Heart, Lung and Blood Institute, 1995.
468. Ressel GW. NAEPP updates guidelines for the diagnosis and management of asthma. *American Family Physician*, 2003, 68:169–170.
469. Lemiere C et al. Adult Asthma Consensus Guidelines Update 2003. *Canadian Respiratory Journal*, 2004, 11:9A–18A.
470. Li J et al. Attaining optimal asthma control: a practice parameter. *Journal of Allergy and Clinical Immunology*, 2005, 116:S3–S11.
471. Bateman ED et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. *American Journal of Respiratory and Critical Care Medicine*, 2004, 170:836–844.
472. O'Byrne P et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. *American Journal of Respiratory and Critical Care Medicine*, 2005, 171:129–136.
473. Sullivan SD et al. Cost-effectiveness analysis of early intervention with budesonide in

- mild persistent asthma. *Journal of Allergy and Clinical Immunology*, 2003, 112:1229–1236.
474. Zwar NA et al. General practitioner views on barriers and facilitators to implementation of the Asthma 3+ Visit Plan. *Medical Journal of Australia*, 2005, 183:64–67.
475. Swartz MK, Banasiak NC, Meadows-Oliver M. Barriers to effective pediatric asthma care. *Journal of Pediatric Health Care*, 2005, 19:71–79.
476. Alvarez GG et al. A systematic review of risk factors associated with near-fatal and fatal asthma. *Canadian Respiratory Journal*, 2005, 12:265–270.
477. Gibson G et al. Self-management education and regular practitioner review for adults with asthma. *Cochrane database of systematic reviews*, 2000, 2.
478. Gibson G et al. Limited (information only) patient education programs for adults with asthma. *Cochrane database of systematic reviews*, 2000, 2.
479. Gibson G Powell H. Written action plans for asthma: an evidence-based review of the key components. *Thorax*, 2004, 59:94–99.
480. Toelle BG, Ram FS. Written individualised management plans for asthma in children and adults. *Cochrane database of systematic reviews*, 2004, 2.
481. Yach D. The use and value of qualitative methods in health research in developing countries. *Social Science and Medicine*, 1992, 35:603–612.
482. Laitinen LA, Koskela K. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998–2007. *Respiratory Medicine*, 1999, 93:297–332.
483. *Programme d'actions, de prévention et de prise en charge de la BPCO, 2001-2005*. (<http://www.sante.gouv.fr>, accessed 25 November 2005).
484. Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. *European Respiratory Journal*, 2003, 22:1–2.
485. Halpin D. NICE guidance for COPD. *Thorax*, 2006, 59:181–182.
486. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax*, 2004, 59.
487. MacNee W, Calverley PM. Chronic obstructive pulmonary disease. 7: Management of COPD. *Thorax*, 2003, 58:261–265.
488. Ferguson GT. Recommendations for the management of COPD. *Chest*, 2000, 117:23S–28S.
489. Russi EW et al. Management of chronic obstructive pulmonary disease: the Swiss guidelines. Official Guidelines of the Swiss Respiratory Society. *Swiss Medical Weekly*, 2002, 132:67–78.
490. Bateman ED et al. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision. *South African Medical Journal*, 2004, 94:559–575.
491. O'Donnell DE et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. *Canadian Respiratory Journal*, 2004, 11:7B–59B.
492. Kitamura S. COPD guideline of Japanese Respiratory Society. *Nippon Rinsho*, 2003, 61:2077–2081.
493. Chan-Yeung M t al. Management of chronic obstructive pulmonary disease in Asia and Africa. *International Journal of Tuberculosis and Lung Diseases*, 2004, 8:504–508.
494. Takahashi T et al. Underdiagnosis and undertreatment of COPD in primary care settings. *Respirology*, 2003, 8:504–508.

495. Lindberg A et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. *Respiratory Medicine*, 2006, 100:264-272.
496. Godtfredsen NS et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. *Thorax*, 2002, 57:967-972.
497. Anthonisen NR. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Annals of Internal Medicine*, 2005, 142:233-239.
498. Simmons MS et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. *European Respiratory Journal*, 2005, 25:1011-1017.
499. Willemse BW et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. *European Respiratory Journal*, 2004, 24:391-396.
500. Rennard SI. Treatment of stable chronic obstructive pulmonary disease. *The Lancet*, 2004, 364:791-802.
501. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. *European Respiratory Journal*, 2005, 25:1084-1106.
502. Calverley PM. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. *Proceedings of the American Thoracic Society*, 2004, 1:121-124.
503. Niewoehner DE. Interventions to prevent chronic obstructive pulmonary disease exacerbations. *American Journal of the Medical Sciences*, 2004, 117:41S-48S.
504. Spencer S et al. Impact of preventing exacerbations on deterioration of health status in COPD. *European Respiratory Journal*, 2004, 23:698-702.
505. Poole PJ et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. *Cochrane database of systematic reviews*, 2000, 4.
506. Lacasse Y et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane database of systematic reviews*, 2002, 3.
507. Puhan MA et al. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review. *Respiratory Research*, 2005, 6:54.
508. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. *European Respiratory Journal*, 2005, 26:630-636.
509. Ries AL et al. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. *Annals of Internal Medicine*, 1995, 122:823-832.
510. Ries AL. Pulmonary rehabilitation and COPD. *Seminars in Respiratory and Critical Care Medicine*, 2005, 26:133-141.
511. Monninkhof E et al. Economic evaluation of a comprehensive self-management programme in patients with moderate to severe chronic obstructive pulmonary disease. *Chronic Respiratory Disease*, 2004, 1:7-16.
512. Tardy SP, Celli BR. Long-term oxygen therapy. *New England Journal of Medicine*, 1995, 333:710-714.
513. MacNee W. Prescription of oxygen: still problems after all these years. *American Journal of Respiratory and Critical Care Medicine*, 2005, 172:517-518.
514. Papi A et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. *Thorax*, 2004, 59:679-681.
515. Mohsenin V. Sleep in chronic obstructive pulmonary disease. *Seminars in Respiratory and Critical Care Medicine*, 2005, 26:109-116.
516. Scanlon PD et al. Loss of bone density with inhaled triamcinolone in Lung Health

- Study II. *American Journal of Respiratory and Critical Care Medicine*, 2004, 170:1302–1309.
517. Boot CR et al. Knowledge about asthma and COPD: associations with sick leave, health complaints, functional limitations, adaptation, and perceived control. *Patient Education and Counseling*, 2005, 59:103–109.
518. *Global strategy on occupational health for all: The way to health at work. Recommendation of the second meeting of the WHO Collaborating Centres in Occupational Health*. Beijing, China, World Health Organization, 1995.
519. Gautrin D, Ghezzi H, Malo JL. Rhinoconjunctivitis, bronchial responsiveness, and atopy as determinants for incident non-work-related asthma symptoms in apprentices exposed to high-molecular-weight allergens. *Allergy*, 2003, 58:608–615.
520. Esterhuizen TM et al. Occupational respiratory diseases in South Africa--results from SORDSA, 1997-1999. *South African Medical Journal*, 2001, 91:502–508.
521. Hnizdo E et al. Occupational asthma as identified by the Surveillance of Work-related and Occupational Respiratory Diseases programme in South Africa. *Clinical & Experimental Allergy*, 2001, 31:32–39.
522. Wagner G. *Screening and surveillance of workers exposed to mineral dusts*. Geneva, World Health Organization, 1996.
523. Nicholson PJ et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. *Journal of Occupational and Environmental Medicine*, 2005, 62:290–299.
524. Ross RM. The clinical diagnosis of asbestosis in this century requires more than a chest radiograph. *Chest*, 2003, 124:1120–1128.
525. Malo JL. Assessment of peak expiratory flow in asthma. *Current Opinion in Pulmonary Medicine*, 1996, 2:75–80.
526. Carroll P, Wachs JE. Managing asthma in the workplace: an overview for occupational health nurses. *American Association of Occupational Health Nurses Journal*, 2004, 52:481–489, quiz 490–491.
527. Humbert M, Sitbon O, Simonneau G. Treatment of arterial pulmonary hypertension. *New England Journal of Medicine*, 2004, 51:1425–1436.
528. Naeije R, Vachiery JL. Medical therapy of pulmonary hypertension. Conventional therapies. *Clinics in Chest Medicine*, 2001, 22:517–527.
529. Sterk PJ et al. The message from the World Asthma Meeting. The Working Groups of the World Asthma Meeting, held in Barcelona, Spain, December 9-13, 1998. *European Respiratory Journal*, 1999, 14:1435–1453.
530. Ait-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. *Bulletin of the World Health Organization*, 2001, 79:971–979.
531. Kunzli N et al. The Global TB Drug Facility: innovative global procurement. *International Journal of Tuberculosis and Lung Diseases*, 2004, 8:130–138.
532. Bilo NE. Do we need an asthma drug facility? *International Journal of Tuberculosis and Lung Diseases*, 2004, 8:391.
533. Coffin SE. Bronchiolitis: in-patient focus. *Pediatric Clinics of North America*, 2005, 52:1047–1057, viii.
534. English M. Impact of bacterial pneumonias on world child health. *Paediatric Respiratory Reviews*, 2000, 1:21–25.
535. Cashat-Cruz M, Morales-Aguirre JJ, Mendoza-Azpiri M. Respiratory tract infections in children in developing countries. *Seminars in Pediatric Infectious Diseases*, 2005, 16:84–92.

536. Graham SM. Non-tuberculosis opportunistic infections and other lung diseases in HIV-infected infants and children. *International Journal of Tuberculosis and Lung Diseases*, 2005, 9:592–602.
537. Gold DR, Wright R. Population disparities in asthma. *Annual Review of Public Health*, 2005, 26:89–113.
538. Okoromah CN, Oviawe O. Is childhood asthma underdiagnosed and undertreated? *Niger Postgraduate Medical Journal*, 2006, 9:221–225.
539. Siersted HC et al. Population based study of risk factors for underdiagnosis of asthma in adolescence: Odense schoolchild study. *British Medical Journal*, 1998, 316:651–655.
540. Bjorkstein B. Unmet needs in the treatment of asthmatic children and adolescents: 2. *Clinical & Experimental Allergy*, 2000, 30:73–76.
541. Ehrlich RI et al. Underrecognition and undertreatment of asthma in Cape Town primary school children. *South African Medical Journal*, 1998, 88:986–994.
542. Riekert KA et al. Caregiver-physician medication concordance and undertreatment of asthma among inner-city children. *Pediatrics*, 2003, 111:e214–e220.
543. Eggleston PA. Environmental causes of asthma in inner city children. The National Cooperative Inner City Asthma Study. *Clinical Reviews in Allergy & Immunology*, 2000, 18:311–324.
544. Federico MJ, Lui AH. Overcoming childhood asthma disparities of the inner-city poor. *Pediatric Clinics of North America*, 2003, 50:655–675, vii.
545. Gellert AR, Gellert SL, Iliffe SR. Prevalence and management of asthma in a London inner city general practice. *British Journal of General Practice*, 1990, 40:197–201.
546. Jones CA et al. A school-based case identification process for identifying inner city children with asthma: the Breathmobile program. *Chest*, 2004, 125:924–934.
547. Velsor-Friedrich B, Pigott T, Srof B. A practitioner-based asthma intervention program with African American inner-city school children. *Journal of Pediatric Health Care*, 2005, 19:163–171.
548. Butz AM et al. Home-based asthma self-management education for inner city children. *Public Health Nursing*, 2005, 22:189–199.
549. Weinberger M. Clinical patterns and natural history of asthma. *Journal of Pediatrics*, 2003, 142:S15–S19, discussion S19–S20.
550. Bundy DG et al. Interpreting subgroup analyses: is a school-based asthma treatment program's effect modified by secondhand smoke exposure? *Archives of Pediatrics & Adolescent Medicine*, 2004, 158:469–471.
551. Heiby JR. Quality improvement and the integrated management of childhood illness: lessons from developed countries. *Joint Commission Journal on Quality Improvement*, 1998, 24:264–279.
552. Moy R. Integrated management of childhood illness (IMCI). *Journal of Tropical Pediatrics*, 1998, 44:190–191.
553. Patwari AK, Raina N. Integrated Management of Childhood Illness (IMCI): a robust strategy. *Indian Journal of Pediatrics*, 2002, 69:41–48.
554. Lulseged S. Integrated management of childhood illness: a review of the Ethiopian experience and prospects for child health. *Ethiopian Medical Journal*, 2002, 40:187–201.